Market Intel: How 3D Printing Can Enhance And Expand Medtech Opportunities
• By Clemens Moeller, Christophe Durand, and Scott Rader
3D printing has been hailed as a potentially game-changing technology for different industries. Biomedical applications, in particular, have garnered much attention when patients were able to receive 3D-printed, customized, lifesaving medical interventions. But aside from these niche markets for personalized medical devices, can 3D printing ever become mainstream in health care? This article, a guest column from leaders at the Boston Consulting Group, explores what the benefits of 3D-printed devices are and how they are driving the uptake of this technology. It also assesses how fast this adoption is happening and evaluates how – and in which biomedical applications and device markets – 3D printing could best enhance products and allow medtech manufacturers to grow their business.
The 3D printing revolution is unfolding in the biomedical arena • Source: Shutterstock
The buzz around 3D printing is growing increasingly louder and the market opportunity this technology can bring to medtech manufacturers is certainly real. The global market for joint reconstruction and replacement is expected to increase to $16bn by 2018. The global market for prescription lenses is valued at approximately $13bn today. Spinal implants are a $9bn market. All of these clinical areas have the potential to be enhanced by 3D-printing technologies.
3D printing has already demonstrated its value across a wide range of industries beyond health care. Companies are using 3D...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.
EnsoData positions itself as device-agnostic and interoperable, with FDA-cleared software that can integrate with all major devices. CEO Mortara said this flexibility helps maximize patient reach by enabling both direct provider engagement and integration with device manufacturers.
Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.
EnsoData positions itself as device-agnostic and interoperable, with FDA-cleared software that can integrate with all major devices. CEO Mortara said this flexibility helps maximize patient reach by enabling both direct provider engagement and integration with device manufacturers.
After multiple warning letters and safety communications, the US FDA has decided to block the import of certain endoscopes from Olympus. In total, the agency’s action pertains to 58 device models manufactured by the Japanese firm used in urinary, respiratory, abdominal and pelvic procedures.
